MEDIFAST (MED)
(Real Time Quote from BATS)
$33.50 USD
-0.07 (-0.21%)
Updated Apr 25, 2024 01:58 PM ET
5-Strong Sell of 5 5
A Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
MED 33.50 -0.07(-0.21%)
Will MED be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MED
Medifast's (MED) Transformation on Track Amid Macro Headwinds
MEDIFAST (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?
MED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Medifast (MED) Soars 5.9%: Is Further Upside Left in the Stock?
Innovations Aid Medifast (MED), Lower Customer Attraction Ails
Medifast (MED) Q4 Earnings Beat Estimates, Revenues Dip Y/Y
Other News for MED
65 Graham Value Stocks: 54 Fit To Buy For April
RSPS: Consumer Staples Dashboard For April
Noteworthy Tuesday Option Activity: MED, WOLF, FCX
Medifast to Announce Financial Results for the First Quarter Ended March 31, 2024
New 52-Week Low Could Prompt More Insider Buying At MED